Generali Investments Management Co LLC Raises Stock Position in Merck & Co., Inc. $MRK

Key Points

• Generali Investments Management Co LLC increased its stake in Merck & Co. (MRK) by 32.2% in Q4 to 49,160 shares (an additional 11,966) worth about $5.175 million, representing 1.0% of its portfolio and MRK's 21st largest holding.
• Merck beat Q4 estimates with $2.04 EPS and $16.40B revenue, set FY2026 guidance of $5.00–$5.15 EPS, and pays a $0.85 quarterly dividend (3.0% yield) while analysts carry a consensus "Moderate Buy" target of $128.47.
• Major catalysts include a multi‑year Google Cloud AI partnership and FDA Priority Review for KEYTRUDA in bladder cancer, but near‑term risks include weakening Gardasil sales in China/Japan and substantial insider selling (~320,176 shares in 90 days).

Generali Investments Management Co LLC grew its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 32.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 49,160 shares of the company's stock after acquiring an additional 11,966 shares during the period. Merck & Co., Inc. accounts for 1.0% of Generali Investments Management Co LLC's portfolio, making the stock its 21st largest holding. Generali Investments Management Co LLC's holdings in Merck & Co., Inc. were worth $5,175,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in MRK. Darwin Wealth Management LLC raised its position in Merck & Co., Inc. by 237.4% in the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company's stock worth $26,000 after acquiring an additional 216 shares during the period. Barnes Dennig Private Wealth Management LLC raised its position in Merck & Co., Inc. by 302.3% in the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company's stock worth $30,000 after acquiring an additional 266 shares during the period. United Financial Planning Group LLC bought a new position in Merck & Co., Inc. in the third quarter worth approximately $31,000. Wealth Watch Advisors INC bought a new position in Merck & Co., Inc. in the third quarter worth approximately $34,000. Finally, Dunhill Financial LLC raised its position in Merck & Co., Inc. by 83.0% in the third quarter. Dunhill Financial LLC now owns 419 shares of the company's stock worth $35,000 after acquiring an additional 190 shares during the period. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Stock Down 2.4%

Shares of MRK stock opened at $111.83 on Friday. The company has a market capitalization of $276.21 billion, a price-to-earnings ratio of 15.36, a PEG ratio of 2.31 and a beta of 0.26. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $125.14. The company's fifty day moving average price is $118.61 and its 200-day moving average price is $106.74. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $2.01 by $0.03. The firm had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The company's revenue was up 5.0% on a year-over-year basis. During the same period last year, the firm earned $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Sell-side analysts expect that Merck & Co., Inc. will post 4.92 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th were given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 3.0%. The ex-dividend date was Monday, March 16th. Merck & Co., Inc.'s dividend payout ratio (DPR) is presently 46.70%.

Wall Street Analysts Forecast Growth

MRK has been the topic of several recent research reports. Wall Street Zen upgraded shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating in a research report on Saturday, March 28th. Barclays initiated coverage on shares of Merck & Co., Inc. in a research report on Friday, February 20th. They issued an "overweight" rating and a $140.00 price target on the stock. Wolfe Research upgraded shares of Merck & Co., Inc. from a "peer perform" rating to an "outperform" rating and set a $135.00 price target on the stock in a research report on Thursday, January 8th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating and set a $150.00 price objective on the stock in a research report on Friday, February 13th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $128.47.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced a multi‑year, enterprise‑wide partnership with Google Cloud to deploy Gemini AI and advanced cloud infrastructure for drug discovery, manufacturing and operations — a strategic move that could improve R&D productivity and long‑term margins. Read More. Read More.
• Positive Sentiment: Merck won FDA Priority Review for KEYTRUDA regimens in muscle‑invasive bladder cancer — a potential near‑term upsid e for oncology revenue if approved, supporting key growth drivers beyond vaccines. Read More.
• Positive Sentiment: Regulatory approval momentum: the company secured FDA approval for Idvynso (doravirine + islatravir) for HIV‑1 treatment, and is cited among defensive/counter‑cyclical stock picks — positives for investor sentiment and diversification of approved products. Read More.
• Neutral Sentiment: Progress on M&A: the Hart‑Scott‑Rodino waiting period expired for Merck’s tender offer to acquire Terns Pharmaceuticals, clearing an antitrust procedural hurdle and bringing the acquisition closer to closing — strategic but not immediately earnings‑material. Read More.
• Negative Sentiment: Vaccines headwinds: reports highlight a sharp slump in Gardasil sales in China and Japan, which pressures MRK’s vaccines revenue into the upcoming Q1 results and raises downside risk to top‑line guidance if the trend persists. Read More. Read More.
• Negative Sentiment: Analyst expectations: several analyst notes expect a decline in Q1 earnings and flag that Merck may lack the near‑term drivers for an earnings beat — this raises the risk of downside surprise and explains short‑term selling pressure. Read More. Read More.

Insider Activity

In other Merck & Co., Inc. news, EVP David Michael Williams sold 5,000 shares of Merck & Co., Inc. stock in a transaction on Friday, February 6th. The shares were sold at an average price of $121.91, for a total value of $609,550.00. Following the sale, the executive vice president directly owned 30,838 shares in the company, valued at approximately $3,759,460.58. The trade was a 13.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jennifer Zachary sold 121,573 shares of Merck & Co., Inc. stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the sale, the executive vice president owned 68,916 shares in the company, valued at approximately $8,211,341.40. This represents a 63.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 320,176 shares of company stock worth $38,281,735. 0.13% of the stock is currently owned by insiders.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.